Literature DB >> 9563486

Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study.

T D de Gruijl1, H J Bontkes, J M Walboomers, M J Stukart, F S Doekhie, A J Remmink, T J Helmerhorst, R H Verheijen, M F Duggan-Keen, P L Stern, C J Meijer, R J Scheper.   

Abstract

T-cell-mediated immune responses against oncogenic human papillomaviruses (HPVs) are believed to play a role in the prevention of cervical carcinogenesis. The in vitro production of interleukin 2 by CD4+ T helper (Th) cells in response to overlapping 20-mer peptides covering the HPV-16 E7 oncoprotein sequence was determined in 72 women with cytological evidence of premalignant cervical intraepithelial neoplasia (CIN) who participated in a nonintervention follow-up (FU) study. In addition, 15 HPV-16 + cervical carcinoma patients were tested. Positive Th cell reactivity was restricted to patients infected by HPV-16 and related types and showed a strong association with viral persistence and disease progression, as evidenced by the high frequency of positive responders among women with persistent HPV-16 infections who ended FU with high-grade CIN III lesions [14 of 15 (93%)]. Women with cervical carcinoma showed responses at a significantly reduced rate [7 of 15 (47%); P = 0.014]. Over the FU period (10-34 months), the level of E7-induced interleukin 2 production from the lymphocytes of CIN patients who had cleared HPV-16 infection showed an inverse correlation with time relative to the last positive HPV DNA test, with 8 of 13 of these patients showing positive responses after clearance. By contrast, among women with persistent HPV-16 infections and developing CIN III lesions (n = 8), there was a rise in Th cell activity over the course of FU. The majority of women responded to an immunogenic region in the carboxyl terminus of the E7 protein (amino acids 67-98). The observed HPV-16 E7-specific Th cell responses may develop as a consequence of increased antigen availability resulting either from clearance or from progression of cervical lesions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9563486

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

Review 1.  Cell-mediated immune response to human papillomavirus infection.

Authors:  M Scott; M Nakagawa; A B Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

2.  Infection with Human Papillomavirus: Update on Epidemiology, Diagnosis, and Treatment.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-02       Impact factor: 3.725

3.  Alterations of T-cell surface markers in older women with persistent human papillomavirus infection.

Authors:  Ana Cecilia Rodríguez; Alfonso J García-Piñeres; Allan Hildesheim; Rolando Herrero; Matthew Trivett; Marcus Williams; Ivannia Atmella; Margarita Ramírez; Maricela Villegas; Mark Schiffman; Robert Burk; Enrique Freer; José Bonilla; Concepción Bratti; Ligia A Pinto
Journal:  Int J Cancer       Date:  2011-02-01       Impact factor: 7.396

4.  CD4+ T cells against human papillomavirus-18 E7 in patients with high-grade cervical lesions associate with the absence of the virus in the cervix.

Authors:  Samantha Seresini; Massimo Origoni; Luigi Caputo; Flavia Lillo; Renato Longhi; Simone Vantini; Anna Maria Paganoni; Maria Pia Protti
Journal:  Immunology       Date:  2010-06-02       Impact factor: 7.397

5.  Human T lymphocyte priming in vitro by haptenated autologous dendritic cells.

Authors:  T Rustemeyer; S De Ligter; B M Von Blomberg; P J Frosch; R J Scheper
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

6.  Cervical and vulvar cancer risk in relation to the joint effects of cigarette smoking and genetic variation in interleukin 2.

Authors:  Shehnaz K Hussain; Margaret M Madeleine; Lisa G Johnson; Qin Du; Mari Malkki; Hui-Wen Wilkerson; Federico M Farin; Joseph J Carter; Denise A Galloway; Janet R Daling; Effie W Petersdorf; Stephen M Schwartz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-07       Impact factor: 4.254

7.  Association of serum cytokines with oral HPV clearance.

Authors:  Jennifer O Lam; Jay H Bream; Elizabeth A Sugar; Christian L Coles; Kathleen M Weber; Robert D Burk; Dorothy J Wiley; Ross D Cranston; Susheel Reddy; Joseph B Margolick; Howard D Strickler; Alicia Wentz; Lisa Jacobson; Yingshi Guo; Weihong Xiao; Maura L Gillison; Gypsyamber D'Souza
Journal:  Cytokine       Date:  2016-04-08       Impact factor: 3.861

8.  Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women.

Authors:  Mayumi Nakagawa; Raphael Viscidi; Ian Deshmukh; Maria Da Costa; Joel M Palefsky; Sepideh Farhat; Anna-Barbara Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

9.  Human papillomavirus 16-specific T cell responses in classic HPV-related vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins.

Authors:  I Bourgault Villada; M Moyal Barracco; S Berville; M L Bafounta; C Longvert; V Prémel; P Villefroy; E Jullian; T Clerici; B Paniel; B Maillère; J Choppin; J G Guillet
Journal:  Clin Exp Immunol       Date:  2009-07-30       Impact factor: 4.330

10.  The influence of human papillomavirus type and HIV status on the lymphomononuclear cell profile in patients with cervical intraepithelial lesions of different severity.

Authors:  Maria Alice G Gonçalves; Edson G Soares; Eduardo A Donadi
Journal:  Infect Agent Cancer       Date:  2009-08-18       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.